Second course of efalizumab improves response in psoriatics

Article

New Orleans-Psoriatic patients who responded partially or not at all to initial treatment with efalizumab (Xanelim) responded more positively and without significant adverse events during a second course of treatment.

Related Videos
Related Content

A Hairy Q&A With Jerry Shapiro, MD

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

A Hairy Q&A With Jerry Shapiro, MD

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

A Hairy Q&A With Jerry Shapiro, MD

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023
© 2023 MJH Life Sciences

All rights reserved.